March 17 (Reuters) - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by ...

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

About a month after Pfizer CEO Albert Bourla, Ph.D., told investors that the Big Pharma’s pipeline pruning was mostly done, ...

Pfizer has reached a turning point.

These companies have impressive track records of navigating the biggest challenges in their industry.

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...

As noted, Merck and Pfizer are both large pharmaceutical companies. Making and selling drugs is complex, expensive, and competitive. There are massive research and development costs involved in ...

They aren't just "pandemic stocks." ...